stichoposide: triterpene glycoside; RN given refers to stichoposide A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 119095 |
| MeSH ID | M0042280 |
| Synonym |
|---|
| stichoposide a |
| stichoposide |
| holotoxins |
| lanost-7-en-18-oic acid, 23-(acetyloxy)-3-((2-o-(6-deoxy-beta-d-glucopyranosyl)-beta-d-xylopyranosyl)oxy)-20-hydroxy-, gamma-lactone, (3beta)- |
| 2-{[2-o-(6-deoxyhexopyranosyl)pentopyranosyl]oxy}-18-oxo-18,20-epoxylanost-7-en-23-yl acetate |
| 37341-37-0 |
| [1-[15-[4,5-dihydroxy-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-2,6,13,17,17-pentamethyl-8-oxo-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-1(20)-en-6-yl]-4-methylpentan-2-yl] acetate |
| DTXSID60958457 |
Stichoposide D (STD) is a marine triterpene glycoside isolated from sea cucumbers.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Stichoposide D (STD) is a marine triterpene glycoside isolated from sea cucumbers. " | ( By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts. Han, JY; Jeong, JS; Ju, MH; Kim, SH; Kwak, JY; Park, ES; Park, JI; Shin, SW; Stonik, VA; Yun, SH, 2015) | 2.1 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " We found that while the site 1 and 2 mutants were modestly (two- to sevenfold) reduced in their ability to cause disease in BALB/c mice, the site 3 mutant, W34A, was as toxic as VT1." | ( Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants. Brunton, JL; Soltyk, AM; Wolski, VM, 2001) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Evaluation of the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in inducing antibody responses among volunteers, which was conducted during the winter season of 1993-1994, is reported." | ( Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Aizawa, C; Hashigucci, K; Hattori, N; Ishidate, T; Kamiya, H; Kurata, T; Nagamine, T; Ogawa, H; Oya, A; Sato, T; Suzuki, Y; Tamura, S; Watanabe, K; Yamashita, R, 1996) | 0.29 |
| "We conducted a field trial to evaluate the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in preventing or attenuating influenza among volunteers during the winter season of 1994-1995." | ( [Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers]. Hashigucci, K; Ishidate, T; Kamiya, H; Kurata, T; Tamura, S, 1997) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (12.77) | 18.7374 |
| 1990's | 9 (19.15) | 18.2507 |
| 2000's | 15 (31.91) | 29.6817 |
| 2010's | 13 (27.66) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.82%) | 5.53% |
| Reviews | 2 (3.64%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 52 (94.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||